FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022286388> ?p ?o ?g. }

• W2022286388 endingPage "1114" @default.
• W2022286388 startingPage "1109" @default.
• W2022286388 abstract "Sorafenib, a new oral multikinase inhibitor with antiangiogenic properties, has demonstrated preclinical and clinical activity against several tumor types. The aims of this study were to validate a method for the measurement of sorafenib in plasma from cancer patients, then to test this method in clinical practice. Following liquid–liquid extraction, the compounds were separated with gradient elution (on a C18 ultrasphere ODS column using a mobile phase of acetonitrile/20 mM ammonium acetate), then detected at 255 nm. The calibration was linear in the range 0.5–20 mg/L. Intra- and inter-assay precision was lower than 7 and 10%, respectively, at 0.5, 3 and 20 mg/L. Plasma sorafenib concentrations were measured in 22 cancer patients (99 samples). The mean trough sorafenib concentration (Cmin) and concentration at peak were 4.3 ± 2.5 mg/L (n = 68, CV = 57.5%) and 6.2 ± 3.0 mg/L (n = 31, CV = 47.5%), respectively. Mean sorafenib Cmin in eight patients who experienced grade 3 drug-related adverse events was approximately 1.5-fold greater than that observed in the remaining patients (7.7 ± 3.6 mg/L vs. 4.4 ± 2.4 mg/L, P = 0.0083). In conclusion, the method was successfully used in routine practice to monitor plasma concentrations of sorafenib in cancer patients. Finally, large interindividual variability and higher exposure in patients experiencing severe toxicity support the need for therapeutic drug monitoring to ensure an optimal exposure to sorafenib." @default.
• W2022286388 created "2016-06-24" @default.
• W2022286388 creator A5005781792 @default.
• W2022286388 creator A5014084371 @default.
• W2022286388 creator A5015222370 @default.
• W2022286388 creator A5033231563 @default.
• W2022286388 creator A5034571954 @default.
• W2022286388 creator A5049641705 @default.
• W2022286388 creator A5057785117 @default.
• W2022286388 creator A5064569765 @default.
• W2022286388 creator A5065121477 @default.
• W2022286388 creator A5088353520 @default.
• W2022286388 date "2009-05-01" @default.
• W2022286388 modified "2023-10-18" @default.
• W2022286388 title "Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice" @default.
• W2022286388 cites W1515542254 @default.
• W2022286388 cites W1997567636 @default.
• W2022286388 cites W1998182640 @default.
• W2022286388 cites W2014582878 @default.
• W2022286388 cites W2018348203 @default.
• W2022286388 cites W2024383458 @default.
• W2022286388 cites W2030718140 @default.
• W2022286388 cites W2037535290 @default.
• W2022286388 cites W2090630294 @default.
• W2022286388 cites W2099259685 @default.
• W2022286388 cites W2100066495 @default.
• W2022286388 cites W2140765540 @default.
• W2022286388 cites W2151507583 @default.
• W2022286388 cites W2151898419 @default.
• W2022286388 cites W2166271687 @default.
• W2022286388 cites W4211144080 @default.
• W2022286388 doi "https://doi.org/10.1016/j.jpba.2009.02.008" @default.
• W2022286388 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19278805" @default.
• W2022286388 hasPublicationYear "2009" @default.
• W2022286388 type Work @default.
• W2022286388 sameAs 2022286388 @default.
• W2022286388 citedByCount "101" @default.
• W2022286388 countsByYear W20222863882012 @default.
• W2022286388 countsByYear W20222863882013 @default.
• W2022286388 countsByYear W20222863882014 @default.
• W2022286388 countsByYear W20222863882015 @default.
• W2022286388 countsByYear W20222863882016 @default.
• W2022286388 countsByYear W20222863882017 @default.
• W2022286388 countsByYear W20222863882018 @default.
• W2022286388 countsByYear W20222863882019 @default.
• W2022286388 countsByYear W20222863882020 @default.
• W2022286388 countsByYear W20222863882021 @default.
• W2022286388 countsByYear W20222863882022 @default.
• W2022286388 countsByYear W20222863882023 @default.
• W2022286388 crossrefType "journal-article" @default.
• W2022286388 hasAuthorship W2022286388A5005781792 @default.
• W2022286388 hasAuthorship W2022286388A5014084371 @default.
• W2022286388 hasAuthorship W2022286388A5015222370 @default.
• W2022286388 hasAuthorship W2022286388A5033231563 @default.
• W2022286388 hasAuthorship W2022286388A5034571954 @default.
• W2022286388 hasAuthorship W2022286388A5049641705 @default.
• W2022286388 hasAuthorship W2022286388A5057785117 @default.
• W2022286388 hasAuthorship W2022286388A5064569765 @default.
• W2022286388 hasAuthorship W2022286388A5065121477 @default.
• W2022286388 hasAuthorship W2022286388A5088353520 @default.
• W2022286388 hasConcept C112705442 @default.
• W2022286388 hasConcept C121608353 @default.
• W2022286388 hasConcept C126322002 @default.
• W2022286388 hasConcept C179998833 @default.
• W2022286388 hasConcept C185592680 @default.
• W2022286388 hasConcept C22979827 @default.
• W2022286388 hasConcept C2778019345 @default.
• W2022286388 hasConcept C2778335254 @default.
• W2022286388 hasConcept C2778695046 @default.
• W2022286388 hasConcept C2779974597 @default.
• W2022286388 hasConcept C2780035454 @default.
• W2022286388 hasConcept C2780272996 @default.
• W2022286388 hasConcept C43617362 @default.
• W2022286388 hasConcept C512399662 @default.
• W2022286388 hasConcept C71924100 @default.
• W2022286388 hasConcept C98274493 @default.
• W2022286388 hasConceptScore W2022286388C112705442 @default.
• W2022286388 hasConceptScore W2022286388C121608353 @default.
• W2022286388 hasConceptScore W2022286388C126322002 @default.
• W2022286388 hasConceptScore W2022286388C179998833 @default.
• W2022286388 hasConceptScore W2022286388C185592680 @default.
• W2022286388 hasConceptScore W2022286388C22979827 @default.
• W2022286388 hasConceptScore W2022286388C2778019345 @default.
• W2022286388 hasConceptScore W2022286388C2778335254 @default.
• W2022286388 hasConceptScore W2022286388C2778695046 @default.
• W2022286388 hasConceptScore W2022286388C2779974597 @default.
• W2022286388 hasConceptScore W2022286388C2780035454 @default.
• W2022286388 hasConceptScore W2022286388C2780272996 @default.
• W2022286388 hasConceptScore W2022286388C43617362 @default.
• W2022286388 hasConceptScore W2022286388C512399662 @default.
• W2022286388 hasConceptScore W2022286388C71924100 @default.
• W2022286388 hasConceptScore W2022286388C98274493 @default.
• W2022286388 hasIssue "4" @default.
• W2022286388 hasLocation W20222863881 @default.
• W2022286388 hasLocation W20222863882 @default.
• W2022286388 hasOpenAccess W2022286388 @default.
• W2022286388 hasPrimaryLocation W20222863881 @default.
• W2022286388 hasRelatedWork W1970460092 @default.

• next